PTC Therapeutics, Inc. (PTCT) FY2026 Q3 P&L / Income Statement

Published Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)

Revenue by Product and Service by Geography

Swipe to see the full flow
PTC Therapeutics, Inc. (PTCT) FY2026 Q3 P&L / Income StatementIncome statement for 2026-07-01 through 2026-09-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUEOPERATINGPRE-TAXNETSephience - UNITED STATESRoyalty revenueTranslarna - InternationalSephience - InternationalEmflaza - UNITED STATESUpstaza/Kebilidi - InternationalUpstaza/Kebilidi - UNITED STATESCollaboration and license revenueAll other products - InternationalTotal revenuesIncome from operationsTotal operating expensesTotal operating expenses(Loss) income before income tax (expense) benefitOther income (expense), net (calculated)Net (loss) income attributable to common stockholdersIncome tax (expense) benefit(Loss) income before income tax (expense) benefit(Loss) incomebefore income tax(expense) benefit−$41.09 MTotal revenuesTotal revenues$357.81 MIncome from operationsIncome from operations$25.11 MNet (loss) income attributable to common stockholdersNet (loss) incomeattributable tocommon stockholders−$51.69 MSephience - UNITED STATESSephience - UNITED STATES$144.80 MTotal operating expensesTotal operatingexpenses$332.69 MIncome tax (expense) benefitIncome tax(expense) benefit$10.61 MRoyalty revenueRoyalty revenue$81.68 MTotal operating expensesTotal operating expenses$332.69 MTranslarna - InternationalTranslarna - International$48.51 MSephience - InternationalSephience - International$37.09 MEmflaza - UNITED STATESEmflaza - UNITED STATES$25.09 MUpstaza/Kebilidi - InternationalUpstaza/Kebilidi - International$10.59 MUpstaza/Kebilidi - UNITED STATESUpstaza/Kebilidi - UNITED STATES$3.96 MOther income (expense), net (calculated)Other income,net (calculated)−$66.20 MCollaboration and license revenueCollaboration and license revenue$229.00 KAll other products - InternationalAll other products - International$5.85 M
Chart details

PTC Therapeutics, Inc. (PTCT) FY2026 Q3 P&L / Income Statement

Income statement for 2026-07-01 through 2026-09-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues
357,807,000 US dollars
Total operating expenses
332,693,000 US dollars
Income from operations
25,114,000 US dollars
Other income (expense), net (calculated)
negative 66,202,000 US dollars
(Loss) income before income tax (expense) benefit
negative 41,088,000 US dollars
Income tax (expense) benefit
10,605,000 US dollars
Net (loss) income attributable to common stockholders
negative 51,693,000 US dollars
Collaboration and license revenue
229,000 US dollars
Royalty revenue
81,684,000 US dollars
Emflaza - UNITED STATES
25,094,000 US dollars
All other products - International
5,851,000 US dollars
Sephience - UNITED STATES
144,795,000 US dollars
Sephience - International
37,090,000 US dollars
Translarna - International
48,511,000 US dollars
Upstaza/Kebilidi - UNITED STATES
3,960,000 US dollars
Upstaza/Kebilidi - International
10,593,000 US dollars
Total operating expenses
332,693,000 US dollars

Chart connections

  • Revenue minus operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
PTC Therapeutics, Inc. (PTCT) FY2026 Q3 P&L / Income Statement Sankey chart, Product and service — Product and Service by Geographical view
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!